BioAlliance Pharma presents results on its new oral Irinotecan nanoparticle formulation for the treatment of advanced colorectal cancer at the American Association for Cancer Research (AACR) 100th Annual Meeting in Denver, April 18 to 22, 2009

BioAlliance Pharma SA (Euronext Paris – BIO), a specialty
pharmaceutical company focused on the treatment of opportunistic infections in cancer and
HIV, has presented results on its oral Irinotecan nanoparticle formulation for the treatment of
advanced colorectal cancer at the American Association for Cancer Research (AACR) 100th
Annual Meeting, in Denver, April 18 to 22, 2009.
Colorectal cancer is the third leading cancer after prostate and breast cancer. Each year,
over one million new cases are diagnosed worldwide. Colorectal cancer is also the second
leading cause of cancer-related death.
One of the most common treatments for colorectal cancer is the combination of Irinotecan
(Camptosar®) and Capecitabine (Xeloda®). Whereas Capecitabine is given orally (2 tablets a
day during 14 days each 21 days), Irinotecan is still administered by intravenous route during
48 hours every 14 days.
Results presented at the AACR Meeting describe a new oral formulation of Irinotecan (IRNSRN)
encapsulated into nanoparticles allowing an oral release of the molecule. The aim of
this new formulation is to combine a better tolerance to a sustained release of Irinotecan
administered orally, thus increasing its efficacy.
Tested on animals, this new formulation orally administrated is well tolerated. Moreover, oral
administration on animals bearing colorectal tumours is shown to induce a similar tumour
growth inhibition to the one observed with Irinotecan administered intravenously, with a
nearly 80% tumour growth inhibition.
About the American Association of Cancer Research (AACR)
The mission of the AACR is to prevent and cure cancer through research, education, communication,
and collaboration. Through its programs and services, the AACR fosters research in cancer and
related biomedical science, accelerates the dissemination of new research findings among scientists
and others dedicated to the conquest of cancer, promotes science education and training and
advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the
world.

090421AACRIrino_EN